What To Expect From CONMED's (CNMD) Q1 Earnings

Medical tech company CONMED (NYSE:CNMD) will be reporting earnings tomorrow after market close. Here’s what you need to know.

CONMED beat analysts’ revenue expectations by 1% last quarter, reporting revenues of $345.9 million, up 5.8% year on year. It was a slower quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates.

Is CONMED a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting CONMED’s revenue to be flat year on year at $313.1 million, slowing from the 5.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.81 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CONMED has missed Wall Street’s revenue estimates three times over the last two years.

Looking at CONMED’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Penumbra delivered year-on-year revenue growth of 16.3%, beating analysts’ expectations by 2.7%, and Boston Scientific reported revenues up 20.9%, topping estimates by 2%. Penumbra traded up 7.2% following the results while Boston Scientific was also up 6.5%.

Read our full analysis of Penumbra’s results here and Boston Scientific’s results here.

Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.2% on average over the last month. CONMED is down 15.8% during the same time and is heading into earnings with an average analyst price target of $74.43 (compared to the current share price of $50.84).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.